Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026)

DiaMedica Therapeutics filings provide 8 years of Return on Capital Employed readings, the most recent being 71.36% for Q1 2026.

  • Quarterly Return on Capital Employed fell 5537.0% to 71.36% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 71.36% through Mar 2026, down 5537.0% year-over-year, with the annual reading at 70.59% for FY2025, 6243.0% down from the prior year.
  • Return on Capital Employed hit 71.36% in Q1 2026 for DiaMedica Therapeutics, down from 63.61% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 8.31% in Q4 2024 and bottomed at 71.36% in Q1 2026.
  • Average Return on Capital Employed over 5 years is 38.91%, with a median of 39.29% recorded in 2023.
  • The largest annual shift saw Return on Capital Employed skyrocketed 3278bps in 2022 before it crashed -5537bps in 2026.
  • DiaMedica Therapeutics' Return on Capital Employed stood at 41.73% in 2022, then rose by 5bps to 39.85% in 2023, then surged by 79bps to 8.31% in 2024, then crashed by -665bps to 63.61% in 2025, then decreased by -12bps to 71.36% in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Return on Capital Employed are 71.36% (Q1 2026), 63.61% (Q4 2025), and 27.15% (Q3 2025).